Nucala (Mepolizumab)

Mepolizumab is a humanized monoclonal antibody that binds interleukin‑5 (IL‑5) with high affinity. By neutralising IL‑5, it blocks the cytokine’s interaction with its receptor on eosinophil precursors and mature eosinophils, preventing their growth, activation, and survival. The resulting drop in eosinophil numbers reduces tissue inflammation in the lungs and sinuses.

The dosing regimen for Nucala is determined by the prescribing clinician based on the approved indication and the patient’s clinical status. Typically the medication is administered as a subcutaneous injection at regular intervals, often every four weeks, but the exact dose and schedule must be set by a qualified healthcare professional.

Safety data for mepolizumab in pregnancy and lactation are limited, and the product carries an unknown pregnancy category. Clinicians should weigh potential benefits against possible risks and discuss treatment options with the patient. Breastfeeding mothers should also consult their healthcare provider before using the drug.

To request Nucala, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Nucala (mepolizumab) shares the anti‑IL‑5 mechanism with drugs such as reslizumab and benralizumab. While all reduce eosinophil counts, dosing frequency and administration routes differ: reslizumab is given intravenously, benralizumab targets the IL‑5 receptor and is administered subcutaneously every eight weeks after an initial loading phase. Choice of therapy depends on patient preference, disease severity and physician judgment.

Nucala must be stored in a refrigerator at 2 °C to 8 °C. Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. Maintaining the cold chain is essential to preserve the drug’s stability and efficacy.

Nucala is given as a subcutaneous injection, usually performed by a healthcare professional in a clinical setting. The injection is administered into the abdomen or thigh using a pre‑filled syringe or autoinjector, following aseptic technique. Patients should be observed for a short period after injection for any immediate reactions.

The most serious adverse events linked to Nucala include severe hypersensitivity reactions such as anaphylaxis, the possible development of anti‑drug antibodies that can diminish therapeutic effect, and rare immune‑mediated conditions like vasculitis or eosinophilic pneumonia. Prompt medical attention is required if any signs of a severe reaction occur.

Nucala should be avoided in individuals with a known hypersensitivity to mepolizumab or any of its excipients. It is also contraindicated in patients who have experienced severe allergic reactions to other monoclonal antibodies targeting IL‑5. Clinicians must assess each patient’s medical history before initiating therapy.